The global microfluidics market size was valued to be around USD 2.5 billion in 2016 and is expected to grow at a CAGR of around 18.4% over the forecast period. The market is expected to boom owing to the increasing demand of the point-of-care (POC) market. Microfluidics devices require a fraction of the sample to interpret the data. The application of microfluidics has allowed the conventional laboratory procedure to be shifted to lab-on-chip.
The potential offered by this sector has attracted both industry and academia to introduce newer techniques of sample identification and technologies that can bring down mechanical errors. According to Florida Atlantic University, inspired by the pregnancy test the scientists have developed a new method to store the microfluidic devices without refrigeration for months enabling developing nations to adopt a reliable and inexpensive way to treat patients.
Paper diagnostic tests are expected to save thousands of lives in the near future. Whitesides (Harvard University chemist) and Yager (biochemist at the University of Washington) are in a process of figuring out an app for paper microfluidics: nucleic acid testing with the grants from the Defense Advanced Research Projects Agency (DARPA). It would enable the medical practitioner to identify and diagnose the number of chronic diseases and infections by detecting pathogen DNA or gene sequences.
Technological advancement is one of the key drivers of the microfluidics market. In February 2017, a team of scientists at Stanford University School of Medicine developed an economical lab on chip device electronics, microfluidics, and inkjet technology. It is a two-part system including microfluidic chamber for cells, an electronic strip, and an inkjet printer. It is capable of counting cells, isolate cells and also capturing single cell form a mixture. This device is anticipated to have applications in diagnostics.
There have been successful applications of microfluidics in the variety of commercial products. For multiplex SNP (single-nucleotide polymorphism) genotyping, Fluidigm’s highly integrated fluidic circuits provide a low cost and high sample throughput solution. Quanta Life uses droplet-based microfluidic technologies in order to perform digital PCR for nucleic acid quantitation. Caliper’s LabChip system uses a glass microfluidic chip to get high throughput fluorescent and electrophoretic analysis of fragments of proteins and nucleic acid.
The market potential is attracting numerous players to expand their market share through collaborations. Collaborations with other market experts enable development of strong product portfolios and newer and improved versions of microfluidic devices/technology. For instance, In July 2015, CEA Tech-Leti announced to continue its collaboration with Illumina, Inc. Through this collaboration, both Leti and Illumina would work on next-generation digital microfluidics technology.
IVD has the largest revenue share in 2015 due to its extensive application such as the POC. Moreover, companies such as Abbott, Roche Diagnostics, Cepheid, and Becton, Dickinson and Company (BD). are adopting microfluidics in the IVD. Abbott i-STAT and Samsung LabGeoPT10 are examples of single-step assays that enable blood glucose testing with a single drop of blood.
The medical device is expected to witness the fastest growth. The key reason attributed to this growth is microfluidic devices offer automation which is the most desired attribute in any medical device. Automation saves time, ensure quality, and reduces the risk of errors. These properties are important in point of care diagnostics of treatable infections. Urgent need for diagnostic devices to make point-of-care more efficient is driving the market microfluidics used in medical devices.
Researchers are trying out new techniques that can offer better platforms for next-generation sequencing. In July 2016, Metagenomics received a European grant of USD 11.51 million for its next-generation screening platform. Researchers at the University of Twente, Netherlands are working on the development of microfluidics devices majorly related to assisted reproductive technologies. With this, it is expected that after fertilization, embryos are able to be introduced in the mothers’ uterus with the help of reservoirs and microfluidic channels.
The application of microfluidics in the field of clinical research is expanding with advanced technologies, such as the introduction of digital microfluidics. In July 2016, the Massachusetts Institute of Technology designed a microfluidics device that tests the effect of electric field on cancer cells. The researchers concluded that range of middle-frequency and low-intensity electric field stopped the cancer cells from growing without affecting the neighboring cells.
Polymer-based microfluidics dominated the material segment in 2015. Polydimethylsiloxane (PDMS) is the most widely material used for fabrication and prototyping in the academic community. The polymer is economical and robust for exploratory research, but with advanced technology, PDMS has been replaced by an alternative that has better elasticity and pressure resistance.
The glass material is majorly used in manufacturing analytical devices. Researchers are developing newer techniques to carry out mass fabrication of glass microchips. In November 2014, an article was published in the Royal Society of Chemistry. The researchers developed a new method for fabricating glass microchips using dry film photoresists (DFR). Wet etching of glass with DFR is a one-step process offering a more economical option as compared to conventional fabrication.
Silicon material is expected to grow at the fastest rate due to its expanding POC diagnostics applications. In July 2016, researchers from the Tufts University in Medford designed a microfluidics device by combining silk and gel solution into a mold. The scaffold was a 3D network of microchannel with rectangular silk hydrogels. The silk gel tolerates different environmental variations such as pH, salinity, and temperature.
North America was the largest segment in the microfluidics market due to the presence of prominent market leaders, introduction of advanced technologies, large number of studies to improve the sample volume optimization techniques, and the strong market growth of POC diagnostics.
Moreover, strong financial backing by organizations is expected to pour in new POC diagnostics for chronic diseases, such as cancer and stroke. For instance, in July 2016, New Jersey Institute of Technology received a research grant of USD 1 million from the W.M. Keck Foundation to develop a microfluidic device. The 3-year project will also develop new fabrication materials such as topological phononic crystals, which have wide array of applications.
In April 2016, researchers from MIT received USD 300,000 from the Koch Institute for Integrative Cancer Research. The grant would be used to develop IllumiRNA platform. This microfluidics device sorts cell population into a droplet of blood.
Asia Pacific is the fastest growing market owing to the developing economy, research infrastructure, and low-cost labor. International players are trying to penetrate the untapped market by introducing their products in the APAC market. In October 2015, Dolomite along with the Chemical and Biological Microsystems Society organized a competition in Korea where the winner was to be offered Dolomite equipment of USD 2,500.
Moreover, in February 2016, Samsung Electronics introduced a wearable lab-on-chip device as a data monitoring and processing device for laboratory test biomarkers. The bioprocessor chip is an integrated device that performs all-in-one tests
Some key industry contributors are Illumina, Inc., Agilent Technologies, Caliper Life Sciences (acquired by PerkinElmer, Inc.), Cepheid, Danaher Corporation, Life Technologies Corporation (acquired by Thermo Fisher Scientific, Inc.), Bio-Rad Laboratories, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, and Fluidigm Corporation.
Companies are introducing new products to strengthen their market position. For instance, In February 2015, Illumina, Inc. launched NeoPrep, an automatic DNA and RNA sample preparation platform. Through the NeoPrep microfluidics cartridge, 16 samples are prepared at a time. Innovation and research & development by the market players in the microfluidics segment are expected to propel the market growth in the coming years.
Attribute |
Details |
Base year for estimation |
2015 |
Actual estimates/Historical data |
2013 - 2015 |
Forecast period |
2016 - 2024 |
Market representation |
Revenue in USD Million & CAGR from 2016 to 2024 |
Regional scope |
North America, Europe, Asia Pacific, Latin America,& MEA |
Country scope |
U.S., Canada, Germany, UK, Japan, China, Brazil, Mexico, & South Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors & trends |
15% free customization scope (equivalent to 5 analyst working days) |
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization |
This report forecasts revenue growth and provides an analysis of the industry trends in each of the sub-segments from 2013 to 2024. For the purpose of this study, Grand View Research has segmented the global microfluidics market report based on application, material, and region:
Application Outlook (Revenue, USD Million, 2013 - 2024)
Pharmaceutical
Genomics
Proteomics
Cell based assays and others
In-Vitro Diagnostics (IVD)
POC
Clinical
Environmental and industrial
Medical Devices
Material Outlook (Revenue, USD Million, 2013 - 2024)
Polymer
Glass
Silicon
Metal, Ceramics and others
Regional Outlook (Revenue, USD Million, 2013 - 2024)
North America
U.S.
Canada
Europe
UK
Germany
Rest of Europe
Asia Pacific
India
Japan
China
Rest of Asia Pacific
Latin America
Brazil
Rest of Latin America
MEA
South Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."